Auspex Pharmaceuticals Company Profile (NASDAQ:ASPX)

About Auspex Pharmaceuticals

Auspex Pharmaceuticals logoAuspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ASPX
  • CUSIP:
Key Metrics:
  • Previous Close: $101.00
  • 50 Day Moving Average: $94
  • 200 Day Moving Average: $59
  • 52-Week Range: $15.00 - $101.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -50.50
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:

Analyst Ratings

Consensus Ratings for Auspex Pharmaceuticals (NASDAQ:ASPX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
DateFirmActionRatingPrice TargetDetails
3/31/2015Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralView Rating Details
3/31/2015Stifel NicolausDowngradeBuy -> Hold$101.00View Rating Details
3/31/2015Robert W. BairdDowngradeOutperform -> Neutral$95.00 -> $101.00View Rating Details
3/30/2015William BlairDowngradeOutperform -> Market Perform$105.00View Rating Details
3/30/2015BMO Capital MarketsDowngradeOutperform -> Market Perform$105.00 -> $101.00View Rating Details
3/30/2015Piper Jaffray CompaniesDowngradeOverweight -> Neutral$91.00 -> $101.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015($0.59)($0.74)ViewN/AView Earnings Details
11/10/2014($0.45)($0.73)ViewN/AView Earnings Details
8/7/2014($0.33)($0.45)ViewN/AView Earnings Details
5/13/2014Q114($0.39)($0.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Auspex Pharmaceuticals (NASDAQ:ASPX)
Current Year EPS Consensus Estimate: $-4 EPS
Next Year EPS Consensus Estimate: $-2 EPS


Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2015David A StamlerInsiderSell3,000$80.00$240,000.00View SEC Filing  
2/13/2015Ventures Vii Lp CmeaMajor ShareholderSell122,667$63.08$7,737,834.36View SEC Filing  
2/11/2015Ventures Vii Lp CmeaMajor ShareholderSell84,154$61.06$5,138,443.24View SEC Filing  
2/6/2015Ventures Vii Lp CmeaMajor ShareholderSell93,179$59.39$5,533,900.81View SEC Filing  
1/28/2015Alex ZissonDirectorSell730,000$53.11$38,770,300.00View SEC Filing  
1/28/2015James E FlynnInsiderBuy1,500,000$56.50$84,750,000.00View SEC Filing  
1/28/2015Panorama Capital, L.P.Major ShareholderSell270,000$53.11$14,339,700.00View SEC Filing  
12/22/2014David A StamlerInsiderSell2,660$53.55$142,443.00View SEC Filing  
12/18/2014Ventures Vii Lp CmeaMajor ShareholderSell195,000$50.14$9,777,300.00View SEC Filing  
10/30/2014Ventures Vii Lp CmeaMajor ShareholderSell19,000$27.15$515,850.00View SEC Filing  
10/28/2014Ventures Vii Lp CmeaMajor ShareholderSell14,500$27.02$391,790.00View SEC Filing  
10/27/2014Ventures Vii Lp CmeaMajor ShareholderSell3,413$27.11$92,526.43View SEC Filing  
10/24/2014Ventures Vii Lp CmeaMajor ShareholderSell16,500$26.97$445,005.00View SEC Filing  
10/6/2014Ventures Vii Lp CmeaMajor ShareholderSell7,109$23.45$166,706.05View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy1,466$21.75$31,885.50View SEC Filing  
9/5/2014Ventures Vii Lp CmeaMajor ShareholderSell25,600$23.86$610,816.00View SEC Filing  
9/3/2014Ventures Vii Lp CmeaMajor ShareholderSell22,700$23.08$523,916.00View SEC Filing  
8/28/2014Ventures Vii Lp CmeaMajor ShareholderSell29,600$22.03$652,088.00View SEC Filing  
8/26/2014Ventures Vii Lp CmeaMajor ShareholderSell6,300$21.35$134,505.00View SEC Filing  
8/22/2014Ventures Vii Lp CmeaMajor ShareholderSell1,700$20.56$34,952.00View SEC Filing  
7/16/2014R Scott GreerDirectorBuy5,190$19.25$99,907.50View SEC Filing  
2/10/2014James E FlynnInsiderBuy700,000$12.00$8,400,000.00View SEC Filing  
2/10/2014Panorama Capital, L.P.Major ShareholderBuy333,334$12.00$4,000,008.00View SEC Filing  
2/10/2014Pratik ShahCEOBuy8,333$12.00$99,996.00View SEC Filing  
2/10/2014Sepehr SarsharDirectorBuy67,263$12.00$807,156.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Auspex Pharmaceuticals (NASDAQ:ASPX)
DateHeadline logoChardan Analyst Suggests An AveXis-Ionis Pair Trade (NASDAQ:ASPX) - February 6 at 3:43 PM
News IconAuspex Pharmaceuticals Inc ASPX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ASPX) - January 19 at 4:47 PM logoHurry! These 5 Stocks Are About to Break Out Explosively (NASDAQ:ASPX) - January 13 at 4:10 PM
News IconAXIM Biotech earns patent for chewing gum containing cannabinoids to treat neurodegenerative diseases (NASDAQ:ASPX) - January 9 at 1:00 AM logoCitron Research On AveXis: This Will Be One Of 2017's Biotech Blowups (NASDAQ:ASPX) - December 15 at 3:28 PM
News IconRegulus announces new two drug development candidates for cholestatic diseases & ADPK treatments (NASDAQ:ASPX) - December 8 at 3:55 PM logoPharma, Biotech Shares Down After Trump Pledge To Cut Drug Prices (NASDAQ:ASPX) - December 8 at 3:55 PM logoSanofi and Regeneron Announce Marketing Authori... (NASDAQ:ASPX) - December 8 at 3:55 PM logoLupin's arm receives USFDA approval for generic Topicort Ointment (NASDAQ:ASPX) - December 8 at 3:55 PM
News IconBreckenridge Pharmaceutical, Inc. Signs Marketing Agreement With Gland Pharma For Seven Injectable Products (NASDAQ:ASPX) - December 8 at 3:55 PM logoAll Eyes on These Two Biotech Firms Ahead of FDA Decisions (VCEL, SGYP) (NASDAQ:ASPX) - December 8 at 3:55 PM
News IconAuspex Pharmaceuticals, Inc. ASPX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ASPX) - November 25 at 8:53 AM logoAveXis reports 3Q loss (NASDAQ:ASPX) - November 10 at 9:44 PM logoShould You Sell AveXis (AVXS) Before Earnings? (NASDAQ:ASPX) - November 9 at 12:31 PM logoCan The Uptrend Continue for AveXis (AVXS)? (NASDAQ:ASPX) - November 4 at 2:00 PM logoHere's Why AveXis Shot Up 24.5% Today (NASDAQ:ASPX) - November 2 at 3:58 PM logoIf you want to know which way the market is heading, follow the leaders (NASDAQ:ASPX) - October 17 at 3:35 PM
News IconRecent Delaware Case Law Clarifies Irrebuttable Business Judgment Rule (NASDAQ:ASPX) - October 14 at 11:46 AM logoAveXis (AVXS) Shows Strength: Stock Adds 6.3% in Session (NASDAQ:ASPX) - September 20 at 9:32 AM logoAveXis reports 2Q loss (NASDAQ:ASPX) - August 11 at 9:29 PM logoWhy AveXis (AVXS) Might Surprise This Earnings Season (NASDAQ:ASPX) - August 9 at 12:26 PM logoRon Baron's Top New Stock Holdings (NASDAQ:ASPX) - May 31 at 11:15 PM logoDeerfield Management’s Top Health Stocks ~ Auspex Pharmaceuticals Inc (ASPX), Horizon Pharma PLC (HZNP), AbbVie Inc (ABBV) (NASDAQ:ASPX) - May 29 at 1:23 PM logoWhy Teva’s Specialty Medicines Performance Declined in 1Q15 (NASDAQ:ASPX) - May 8 at 11:07 PM logoAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquis (NASDAQ:ASPX) - May 5 at 4:50 PM logoTeva Completes Acquisition of Auspex Pharmaceuticals (NASDAQ:ASPX) - May 5 at 2:03 PM logoTeva 1Q15 Earnings Preview: Stock Up 10.3% since Last Quarter (NASDAQ:ASPX) - April 29 at 3:06 AM logoTeva Earnings Preview: Auspex Acquisition to Support Growth (NASDAQ:ASPX) - April 28 at 9:06 PM logoMylan rejects Teva's $40.1 billion buyout offer (NASDAQ:ASPX) - April 27 at 11:35 AM logoTeva offers to buy Mylan in $40.1B cash-and-stock deal (NASDAQ:ASPX) - April 21 at 5:30 PM logoInvesting in IPOs: Why Investors Should Proceed with Caution (NASDAQ:ASPX) - April 20 at 8:02 AM logoMylan skeptical of rumored Teva bid; hasn't received offer (NASDAQ:ASPX) - April 17 at 5:29 PM logoAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ASPX) - April 17 at 9:02 AM logoPharmacyclics, Inc. (PCYC), Horizon Pharma PLC (HZNP), Auspex Pharmaceuticals Inc (ASPX): Hedge Fund’s Cashing In On Highest Q1 Gainers (NASDAQ:ASPX) - April 2 at 11:54 AM logoThe Bull Case: Supply & Demand Edition (NASDAQ:ASPX) - March 31 at 10:14 AM
News IconBiz Break: Brisbane biotech bought for $1.1 billion as boom barrels on (NASDAQ:ASPX) - March 30 at 7:03 PM logoGLOBAL MARKETS-Stocks rally on merger activity; dollar gains (NASDAQ:ASPX) - March 30 at 4:38 PM


What is Auspex Pharmaceuticals' stock symbol?

Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."

How do I buy Auspex Pharmaceuticals stock?

Shares of Auspex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Auspex Pharmaceuticals stock cost?

One share of Auspex Pharmaceuticals stock can currently be purchased for approximately $101.00.

Auspex Pharmaceuticals (NASDAQ:ASPX) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)

Earnings History Chart

Earnings by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)

Dividend History Chart

Dividend Payments by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)

Last Updated on 2/24/2017 by Staff